Integrating network pharmacology, pharmacokinetics and experimental validation to reveal the potential mechanism of Physochlaina physaloides (L.) G. Don in chronic atrophic gastritis.

Abstract

ETHNOPHARMACOLOGICAL RELEVANCE: Physochlaina physaloides (L.) G. Don, abbreviated as P. physaloides, is a traditional folk medicine, has been extensively utilized for alleviating inflammatory response in gastrointestinal tract. Recent research on P. physaloides has predominantly focused on the identification and isolation of chemical components, but there is a scarcity of studies that discover active ingredients and explore mechanism of action. AIM OF THE STUDY: Our research was aimed at identifying the bioactive constituents of P. physaloides, and clarify their potential mechanisms for treating chronic atrophic gastritis (CAG). MATERIALS AND METHODS: A "bioactive constituent-core target-key pathway" network was constructed to predict the underlying therapeutic targets of P. physaloides in the therapy of CAG. The association between the bioactive constituent and its corresponding target was substantiated through molecular docking analysis. An efficient and versatile UHPLC-MS/MS method was formulated and verified to quantify the bioactive constituent across multiple biological matrices among rats. Furthermore, the MNNG-induced CAG cellular model and rat model were established. The pharmacological effects of the bioactive constituent were investigated using CCK-8 assays, invasion assays, migration assays, flow cytometry, H&E staining, ELISA kit and Western blot. RESULTS: The 47 compounds were found to interact with 1892 corresponding targets, among which 217 disease-associated targets specifically related to CAG were recognized. Among these, physochloside D demonstrated potential binding affinity with STAT3 and JAK2, respectively. Pharmacokinetics and excretion studies in rats revealed that physochloside D is rapidly absorbed but exhibits low bioavailability, undergoing a high degree of biotransformation in vivo. it was indicated that physochloside D effectively mitigates MNNG-induced damage to GES-1 cells and attenuates gastric mucosal atrophy. Furthermore, physochloside D modulates the JAK2/STAT3 signaling pathway, thereby suppressing apoptosis and intestinal metaplasia. Therefore, the development of CAG was hindered. CONCLUSION: Overall, this research demonstrated that P. physaloides holds potential as a promising therapeutic agent for CAG. As a specific suppressor of the JAK2/STAT3 signaling pathway, physochloside D is the primary active constituent, which is regarded as a compelling contender for CAG therapy.